Biotech Values

[biomaven0]

I looked at the Rigel presentations briefly, but only caught a small part of their presentation.

The one new thing they present is that for TASKi3 (the failed trial) there was a significant difference between patients that entered via an elevated CRP (where the drug was on the border of being statistically superior and was p<.002 superior on DAS28) and those that entered via an elevated ESR but normal CRP, where the placebo was numerically dramatically better than the drug.

This may well just be a statistical artifact, or it may be indicative that the ESR was fudged by some trial sites to get patients who didn't really have active disease into the trial. (The CRP was measured at a central site, the ESR locally).

I'm pretty sure this is an active, partnerable drug. But at this point it does have some warts because of the hypertension issue and the failed TASKi3.